Michael Dougherty - 31 Jan 2024 Form 4 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Role
Chief Financial Officer
Signature
/s/ Maria Zannes, as attorney-in-fact for Michael Dougherty
Issuer symbol
BIAF
Transactions as of
31 Jan 2024
Transactions value $
$0
Form type
4
Filing time
02 Feb 2024, 16:17:53 UTC
Previous filing
06 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIAF Common Stock Award $0 +31,847 +61% $0 84,203 31 Jan 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024.